Ionis Pharmaceuticals Stock Forecast, Price & News

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

How has Ionis Pharmaceuticals' stock price been impacted by COVID-19?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS stock has decreased by 40.0% and is now trading at $29.50.
View which stocks have been most impacted by COVID-19.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Ionis Pharmaceuticals.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.05. The company earned $133 million during the quarter, compared to analyst estimates of $162.01 million. Ionis Pharmaceuticals had a negative net margin of 89.71% and a negative trailing twelve-month return on equity of 89.95%. The business's revenue for the quarter was down 16.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) earnings per share.
View Ionis Pharmaceuticals' earnings history.

What price target have analysts set for IONS?

9 brokers have issued 12-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $31.00 to $68.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $49.06 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:

• Brett P. Monia, Chief Executive Officer & Director
• Joel Edwards, Vice President-Corporate & Commercial Operations
• Elizabeth L. Hougen, Chief Financial Officer & Executive VP-Finance
• C. Frank Bennett, Chief Scientific Officer & Executive VP
• Sanjay Bhanot, Chief Medical Officer

Who are some of Ionis Pharmaceuticals' key competitors?

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of IONS's competitors.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (6.62%), Camber Capital Management LP (1.77%), Geode Capital Management LLC (1.26%), Rockefeller Capital Management L.P. (0.94%), Candriam Luxembourg S.C.A. (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.49%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Bellevue Group AG, Millennium Management LLC, Invesco Ltd., International Biotechnology Trust PLC, Caption Management LLC, and Two Sigma Advisers LP. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Candriam Luxembourg S.C.A., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Squarepoint Ops LLC, and Tudor Investment Corp Et Al.
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $29.50.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $4.17 billion and generates $729 million in revenue each year. The company earns $-451.29 million in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 757 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700.